Enasidenib Mesylate | m-entrepreneurship.com

Product Name :
Enasidenib Mesylate

Search keywords :
Enasidenib (mesylate)

drugId :
null

Target Vo:
Isocitrate dehydrogenase [NADP], mitochondrial

Target Vo Short Name :
IDH2

Moa_Name:
Isocitrate dehydrogenase [NADP], mitochondrial inhibitors

First Approval Country :
United States

First Approval Date Filter:
2017

Origin Company_Name :
Celgene Corp

Active Company_Name :
Agios Pharmaceuticals Inc

Active Indication_Name:
Leukemia, Myeloid, Acute

In Active Indication_Name:
Lymphoma, T-Cell

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
GPR43 Antibody
AMPK alpha 1 Antibody
eNOS Antibody: eNOS Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 133 kDa, targeting to eNOS. It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts